Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Pfizer vs. Merck

TheMotleyFool

0 0

Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are both multinational pharmaceutical heavyweights, complete with massive development pipelines, numerous subsidiaries, and consistently profitable operations. With nearly identical market caps in the $200 billion range, Merck and Pfizer appear to be two of the most evenly matched competitors in the pharmaceutical sector.

So, how should potential investors choose between these two seemingly similar stocks? Let's examine the merits of each more closely.

Image Source: Getty Images.

Source Fool.com

Like: 0

MRK

Share